Stryker’s sales unit in Michigan previously secured a US$100.00 million contract modification from the U.S. Defense Logistics Agency, underscoring its role as a key supplier to government healthcare and logistics systems. This award highlights the importance of stable government contracting as a complement to Stryker’s hospital and surgical product revenue mix. We’ll now examine how this sizable Defense Logistics Agency contract influences Stryker’s investment narrative, particularly its...

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.

Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker’s share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return is up 23.40%, and...

Check out the companies making headlines yesterday:

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Despite its disappointing performance relative to the broader market over the past year, Stryker continues to enjoy strong backing from Wall Street.

Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $100 million contract modification from the US Defense Logistics Agency.

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

Mercury Systems (NASDAQ:MRCY) reported record fourth-quarter bookings, backlog and revenue for fiscal 2026, as the defense technology company cited broad demand across its portfolio and raised its long-term organic-growth target. Chairman and Chief Executive Officer Bill Ballhaus said fourth-quarte

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across its main divisions that was driven by customer volume rather than acquisitions. A wide gap between reported and adjusted earnings raised questions about ongoing costs that are weighing on profitability. For readers interested in other income focused healthcare ideas, the next logical step is to explore 11 dividend...

Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Stryker's medical...

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday.

Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

PBH vs. SYK: Which Stock Is the Better Value Option?

Bill Shields, who led transcatheter mitral and tricuspid therapies at Medtronic, has joined Versa Vascular, developer of a valve repair treatment.

Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that […]

Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift rather than a warning.

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near the bottom regretting it.

CEO Lobo discusses 9% organic sales growth and margin expansion amid cybersecurity recovery.

Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change with its stock at $85.44 and a value score of 5, which can help...

Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker’s move has you reassessing healthcare exposure,...

Stryker Corporation’s recently reported Q2 2026 results showed sales rising to US$6,589 million and net income to US$1,276 million, with both basic and diluted EPS from continuing operations increasing compared with the prior year period. Management also highlighted 9% organic sales growth, recovery progress after a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. We will now examine how this...

Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.

Stryker (NYSE:SYK) reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year. Chair and CEO Kevin Lobo said the co

Shares of medical technology company Stryker (NYSE:SYK) fell 7.3% in the morning session after the company reported second-quarter results that showed revenue that only met Wall Street's expectations and organic sales growth that missed forecasts.

Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.

CEO Kevin Lobo said the company is working through a backlog of orders and grappling with a supply disruption related to Inari Medical.

Stryker was hit by a cyberattack that disrupted its global operations in March 2026.

Stryker Corp (SYK) delivers robust Q2 2026 results with 17.9% adjusted EPS growth, while navigating supply disruptions and narrowing full-year guidance.

CEO Lobo discusses 9% organic sales growth and margin expansion amid cybersecurity recovery.

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Stryker (SYK) delivered earnings and revenue surprises of +6.65% and +0.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The medical technology company reported a profit of $1.28 billion and and said it has made progress in recovering from a March cyberattack.

Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.

ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.